Beta2-Agonists for Chronic Obstructive Pulmonary Disease (COPD)

Search Knowledgebase

Topic Contents

Beta2-Agonists for Chronic Obstructive Pulmonary Disease (COPD)

Examples

Prescription beta2-agonists

Generic NameBrand Name
salbutamol (short-acting) Ventolin
formoterol (long-acting)Foradil
salmeterol (long-acting)Serevent
terbutaline (short-acting)Bricanyl Turbuhaler

Prescription long-acting beta2-agonist and corticosteroid combination

Generic NameBrand Name
formoterol and budesonideSymbicort
salmeterol and fluticasoneAdvair

Prescription short-acting beta2-agonist and anticholinergic combination

Generic NameBrand Name
salbutamol and ipratropiumCombivent

Beta2-agonists are available in metered-dose inhaler (MDI), nebulizer, pill, injected, and syrup forms. Some beta2-agonists may be available in multiple forms. Your doctor will help you decide which form is best for you.

There are 2 types of beta2-agonists: short-acting and long-acting. The short-acting type relieves symptoms and the long-acting type helps prevent breathing problems. Short-acting beta2-agonists are used for treating stable COPD in a person whose symptoms come and go (intermittent symptoms). Long-acting beta2-agonists are effective and convenient for preventing and treating COPD in a person whose symptoms do not go away (persistent symptoms).

How It Works

Beta2-agonists are bronchodilators. This means that they relax and enlarge (dilate) the airways in the lungs, making breathing easier.

Why It Is Used

Beta2-agonists are considered first-line therapy for the treatment of stable chronic obstructive pulmonary disease (COPD) with symptoms that come and go (intermittent symptoms). They are used for both short- and long-term relief of symptoms.

Beta2-agonists also may be used before exercise to reduce breathing difficulties.

Salmeterol or formoterol may be taken to prevent shortness of breath or coughing that may keep you from exercising.

How Well It Works

Studies indicate that inhaled beta2-agonists are effective in treating symptoms of COPD and improving lung function as measured by tests (spirometry).1 They also reduce the number of COPD exacerbations. There is no evidence of their effect on the progression of the disease.5

Compared to placebo:

  • Inhaled short-acting beta2-agonists are effective in treating a person whose symptoms are rapidly getting worse (COPD exacerbation) and improving lung function and shortness of breath in stable COPD.3, 5
  • Inhaled long-acting beta2-agonists improve lung function and improve symptoms such as shortness of breath.5

Results vary from one person to the next. For some people with COPD, beta2-agonist medicines make breathing much easier. For others, they do not help.

Combining medicines may help your lung function. Using a beta2-agonist:

  • With an anticholinergic may help your lung function more than using either medicine alone.5
  • With an inhaled corticosteroid may result in improved shortness of breath and less use of relief medicine compared to placebo or compared to either medicine used alone.4, 2 The combination also resulted in fewer COPD exacerbations compared with placebo, but it increased the risk of pneumonia.4

Combining medicines also may reduce the risk of side effects compared to increasing the dose of one medicine.6

Side Effects

Side effects are much more likely to occur when you take this medicine as a pill or injection than when you use the inhaled form. Side effects can include:

  • Anxiety.
  • Muscle tremors.
  • Nervousness.
  • Increased or irregular heartbeat (palpitations).

The U.S. Food and Drug Administration (FDA) has reported that formoterol and salmeterol may make breathing more difficult. If your wheezing gets worse after taking these medicines, call your doctor right away.

See Drug Reference for a full list of side effects. (Drug Reference is not available in all systems.)

What To Think About

While short-acting beta2-agonists may be the first choice for treating symptoms of mild COPD that come and go (intermittent symptoms), anticholinergics generally are regarded as the first-line treatment for persistent symptoms, in most cases of COPD.

Inhalation is the preferred method of taking beta2-agonists. This method reduces the chance of side effects and makes the medicine more effective. Pills and injections are reserved for those who cannot use a metered-dose inhaler (MDI) or nebulizer.

Nebulizers normally are no better at delivering beta2-agonists deep into the lungs than a properly used metered-dose inhaler. Sometimes your doctor may prescribe a nebulizer. Although a nebulizer can deliver a very large dose of medicine, it also may increase side effects of the medicine.

Most doctors recommend that everyone using an inhaler also use a spacer. Use of a spacer is especially important when using an inhaler containing a steroid medicine. But you should not use a dry powder inhaler (DPI) with a spacer.

Complete the new medication information form (PDF) (What is a PDF document?) to help you understand this medication.

References

Citations

  1. Celli BR, et al. (2008). Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: Results from the TORCH study. American Journal of Respiratory and Critical Care Medicine, 178(4): 332–338.
  2. Hanania NA, et al. (2003). The efficacy and safety of fluticasone propionate (250 micrograms)/salmeterol (50 micrograms) combined in the Diskus Inhaler for the treatment of COPD. Chest, 124: 834–843.
  3. Stoller JK (2002). Acute exacerbations of chronic obstructive pulmonary disease. New England Journal of Medicine, 346(13): 987–994.
  4. Calverley PM, et al. (2007). Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine, 356(8): 775–789.
  5. Kerstjens H, et al. (2008). COPD, search date March 2007. Online version of BMJ Clinical Evidence: http://www.clinical evidence.com.
  6. Global Initiative for Chronic Obstructive Lung Disease (2009). In Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Available online: http://www.goldcopd.com.

Credits

By Healthwise Staff
Primary Medical Reviewer Caroline S. Rhoads, MD - Internal Medicine
Primary Medical Reviewer Brian D. O'Brien, MD - Internal Medicine
Specialist Medical Reviewer Ken Y. Yoneda, MD - Pulmonology
Last Revised July 9, 2010

This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information.